Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: A cross-sectional study

Journal of Palliative Medicine

Volumn 13, Issue 3, 2010, Pages 291-295

  Bhatnagar, Sushma ^a   Upadhyay, Surjya ^a   Mishra, Seema ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; AMITRIPTYLINE; GABAPENTIN; IBUPROFEN; MORPHINE; PARACETAMOL; PREGABALIN;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER STAGING; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; QUESTIONNAIRE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS-SECTIONAL STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAIN;

EID: 77649299712     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.0266     Document Type: Article

References (21)

1. Portenoy RK, Hagen NA: Breakthrough cancer pain: Definition and manifestations. Prim Care Cancer 1991;21:27-33.
2. Portenoy RK, Hagen NA: Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-281.
3. McQuay HJ, Jadad AR: Incident pain. Cancer Surv 1994;21: 17-24.
4. Farrar JT, Young Jr JP, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
5. Van der Roer N, Ostelo RW, Bekkering GE, van Tulder MW, de Vet HC: Minimal clinically important change for pain intensity, functional status, and general health status in patients with nonspecific low back pain. Spine 2006; 31:578-582.
6. Ostelo R, de Vet HCW. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol 2005;19:593-607. (Pubitemid 40790489)
7. Portenoy RK, Taylor D, Messina J, Tremmel L: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006; 22:805-811. (Pubitemid 44627444)
8. Portenoy RK, Messina J, Xie F, Peppin J: Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: A randomized, placebocontrolled study. Curr Med Res Opin 2007;23:223-233. (Pubitemid 46191684)
9. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK: Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) andmorphine sulfate immediate release (MSIR). Pain 2001;91:123-130.
10. Bennett D, Burton A, Fishman S, Fortner B: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 Management. Pharmacol Ther 2005;30:354-361. (Pubitemid 40885216)
11. Gómez-Batiste X, Madrid F, Gracia A, Trelis J, Nabal M, Alcalde R, Planas J, Camell H: Breakthrough cancer pain: Prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24:45-52.
12. Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, Jackson KA, Lickiss N, Muirden N, Pisasale M, Moulin D, Schulz VN, Rico Pazo MA, Serrano JA, Andersen H, Henriksen HT, Mejholm I, Sjogren P, Heiskanen T, Kalso E, Pere P, Poyhia R, Vuorinen E, Tigerstedt I, Ruismaki P, Bertolino M, Larue F, Ranchere JY, Hege-Scheuing G, Bowdler I, Helbing F, Kostner E, Radbruch L, Kastrinaki K, Shah S, Vijayaram S, Sharma KS, Devi PS, Jain PN, Ramamani PV, Beny A, Brunelli C, Maltoni M, Mercadante S, Plancarte R, Schug S, Engstrand P, Ovalle AF, Wang X, Alves MF, Abrunhosa MR, Sun WZ, Zhang L, Gazizov A, Vaisman M, Rudoy S, Gomez Sancho M, Vila P, Trelis J, Chaudakshetrin P, Koh ML, Van Dongen RT, Vielvoye-Kerkmeer A, Boswell MV, Elliott T, Hargus E, Lutz L; Working Group of an IASP Task Force on Cancer Pain; Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-183.
13. Hays H, Hagen N, Thirlwell M, Dhaliwal H, Babul N, Harsanyi Z, Darke AC: Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 1994;74: 1808-1816.
14. Mercadante S, Armata M, Salvaggio L: Pain characteristics of advanced lung cancer patients referred to a palliative care service. Pain 1994;59:141-145.
15. Mercadante S: What is the definition of breakthrough cancer pain? Pain 1991;45:107.
16. Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI: Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991;337:465-468.
17. Finn JW, Walsh TD, MacDonald N, Bruera E, Krebs LU, Shepard KV: Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 1993;11:967-972.
18. Portenoy RK, Maldonado M, Fitzmartin R, Kaiko RF, Kanner R: Oral controlled-release morphine sulfate: Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patients. Cancer 1989;63:2284-2288.
19. Gutgsell T, Walsh D, Zhukovsky DS, Gonzales F, Lagman R: A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population. Am J Hospice Palliative Care 2003;20:140-148.
20. Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F; Steering Committee of the European Association for Palliative Care (EAPC) Research Network: Episodic (breakthrough) pain: Consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;94: 832-839.
21. Hwang SS, Chang VT, Kasimis B: Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64.